BSACI Guidance for the Implementation of Palforzia® Peanut Oral Immunotherapy - BSACI

BSACI Guidance for the Implementation of Palforzia® Peanut Oral Immunotherapy

To view the full article click here.

Summary

Palforzia® enables the safe and effective desensitisation of children with peanut allergy. The treatment pathway requires multiple visits for dose escalation, up-dosing, monitoring of patients taking maintenance therapy and conversion onto daily real-world peanut consumption. The demand for peanut immunotherapy outstrips current National Health Service (NHS) capacity and requires services to develop a national consensus on how best to offer Palforzia® in a safe and equitable manner. BSACI undertook a Delphi consensus exercise to determine guidance statements for the implementation of Palforzia® based immunotherapy in the NHS.

Read the guidance.

Authors: Nick Makwana and Thomas Marrs

Click here to read the press release.

Announcement

Project Manager for National Allergy Strategy

Read more